JP2585216C

JP2585216C -

Info

Publication number: JP2585216C
Authority: JP; Japan
Prior art keywords: hyaluronic acid; salt; solution; acid; molecular weight
Prior art date: 1999-09-13
Legal status : Expired - Lifetime

Application number

Other languages

English (en)

Japanese (ja)

Original Assignee

フイデイーア・ソシエタ・ペル・アチオニ

Publication date

1999-09-13

Links

229920002674 hyaluronan Polymers 0.000 claims description 237
229960003160 hyaluronic acid Drugs 0.000 claims description 232
MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims description 214
239000011780 sodium chloride Substances 0.000 claims description 156
150000003839 salts Chemical class 0.000 claims description 134
239000000203 mixture Substances 0.000 claims description 115
239000002253 acid Substances 0.000 claims description 77
-1 lolitetracycline Chemical compound 0.000 claims description 70
239000003814 drug Substances 0.000 claims description 64
239000000126 substance Substances 0.000 claims description 54
UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 37
229940079593 drugs Drugs 0.000 claims description 35
QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 33
229960004927 neomycin Drugs 0.000 claims description 29
229960001416 pilocarpine Drugs 0.000 claims description 29
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 24
229960002518 gentamicin Drugs 0.000 claims description 24
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 24
230000003115 biocidal Effects 0.000 claims description 18
230000001264 neutralization Effects 0.000 claims description 18
SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 17
229960005322 Streptomycin Drugs 0.000 claims description 17
239000007864 aqueous solution Substances 0.000 claims description 16
108010093965 Polymyxin B Proteins 0.000 claims description 14
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 14
239000003242 anti bacterial agent Substances 0.000 claims description 14
239000003795 chemical substances by application Substances 0.000 claims description 14
229960000318 kanamycin Drugs 0.000 claims description 14
229960005266 polymyxin B Drugs 0.000 claims description 14
229920000024 polymyxin B Polymers 0.000 claims description 14
IUAYMJGZBVDSGL-XNNAEKOYSA-N Gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 claims description 13
102100010813 EGF Human genes 0.000 claims description 12
101700033006 EGF Proteins 0.000 claims description 12
230000036961 partial Effects 0.000 claims description 12
229940116977 Epidermal Growth Factor Drugs 0.000 claims description 11
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 11
229940014041 hyaluronate Drugs 0.000 claims description 11
TZCXTZWJZNENPQ-UHFFFAOYSA-L Barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 10
230000003110 anti-inflammatory Effects 0.000 claims description 10
229960003276 erythromycin Drugs 0.000 claims description 10
LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 9
229940064005 Antibiotic throat preparations Drugs 0.000 claims description 9
229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 9
229940042052 Antibiotics for systemic use Drugs 0.000 claims description 9
229940042786 Antitubercular Antibiotics Drugs 0.000 claims description 9
229940093922 Gynecological Antibiotics Drugs 0.000 claims description 9
229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims description 9
159000000009 barium salts Chemical class 0.000 claims description 9
229940079866 intestinal antibiotics Drugs 0.000 claims description 9
229940005935 ophthalmologic Antibiotics Drugs 0.000 claims description 9
229960004905 Gramicidin Drugs 0.000 claims description 8
108010026389 Gramicidin Proteins 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 8
229910052782 aluminium Inorganic materials 0.000 claims description 8
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 8
229930006677 A03BA01 - Atropine Natural products 0.000 claims description 7
RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 7
229960000396 Atropine Drugs 0.000 claims description 7
WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 7
229960004821 amikacin Drugs 0.000 claims description 7
229960005091 Chloramphenicol Drugs 0.000 claims description 6
229910052783 alkali metal Inorganic materials 0.000 claims description 6
150000001340 alkali metals Chemical class 0.000 claims description 6
230000000844 anti-bacterial Effects 0.000 claims description 6
229910052788 barium Inorganic materials 0.000 claims description 6
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium(0) Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
229910052749 magnesium Inorganic materials 0.000 claims description 5
239000011777 magnesium Substances 0.000 claims description 5
150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 5
230000036912 Bioavailability Effects 0.000 claims description 4
229960000625 Oxytetracycline Drugs 0.000 claims description 4
IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 4
239000004100 Oxytetracycline Substances 0.000 claims description 4
ZBMZVLHSJCTVON-UHFFFAOYSA-N Sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims description 4
229960002370 Sotalol Drugs 0.000 claims description 4
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
150000001342 alkaline earth metals Chemical class 0.000 claims description 4
230000003444 anaesthetic Effects 0.000 claims description 4
230000035514 bioavailability Effects 0.000 claims description 4
235000019366 oxytetracycline Nutrition 0.000 claims description 4
230000000699 topical Effects 0.000 claims description 4
TWUSDDMONZULSC-HZMBPMFUSA-N (1R,2S)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@@H](O)[C@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-HZMBPMFUSA-N 0.000 claims description 3
RZPAKFUAFGMUPI-ZRLKJDMJSA-N (3R,5R,6S,7S,8S,9S,12S,13R,14R,15R)-6-[(2S,3R,4S,6S)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-8-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-1,11-dioxaspiro[2.13]hexadecane-10,16-dione Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@H](C)C(=O)O[C@@H](C)[C@H](C)[C@@H](O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@H](C)O2)N(C)C)O)[C@@H]1C RZPAKFUAFGMUPI-ZRLKJDMJSA-N 0.000 claims description 3
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 3
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 3
ACTOXUHEUCPTEW-BOISPSKTSA-N 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16S)-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5R,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BOISPSKTSA-N 0.000 claims description 3
229940035674 ANESTHETICS Drugs 0.000 claims description 3
UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 3
229960002274 Atenolol Drugs 0.000 claims description 3
229960003071 Bacitracin Drugs 0.000 claims description 3
108010001478 Bacitracin Proteins 0.000 claims description 3
HQIRNZOQPUAHHV-UHFFFAOYSA-N Bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 claims description 3
229960004475 Chlortetracycline Drugs 0.000 claims description 3
108010078777 Colistin Proteins 0.000 claims description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
OJMMVQQUTAEWLP-KIDUDLJLSA-N Lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 3
229960003439 Mebendazole Drugs 0.000 claims description 3
BAXLBXFAUKGCDY-UHFFFAOYSA-N Mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims description 3
229960002329 Methacholine Drugs 0.000 claims description 3
IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
239000004104 Oleandomycin Substances 0.000 claims description 3
PHUTUTUABXHXLW-UHFFFAOYSA-N Pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 3
AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 3
239000004187 Spiramycin Substances 0.000 claims description 3
229960002673 Sulfacetamide Drugs 0.000 claims description 3
SKIVFJLNDNKQPD-UHFFFAOYSA-N Sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims description 3
229940032484 Sulfisoxazole Drugs 0.000 claims description 3
NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfizole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 3
229960000707 Tobramycin Drugs 0.000 claims description 3
NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 3
229960003636 Vidarabine Drugs 0.000 claims description 3
230000000840 anti-viral Effects 0.000 claims description 3
239000003443 antiviral agent Substances 0.000 claims description 3
OIRDTQYFTABQOQ-UHTZMRCNSA-N arabinosyl adenine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 3
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 3
229960000330 bupranolol Drugs 0.000 claims description 3
235000019365 chlortetracycline Nutrition 0.000 claims description 3
229960003346 colistin Drugs 0.000 claims description 3
XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 claims description 3
229960002222 dihydrostreptomycin Drugs 0.000 claims description 3
ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 claims description 3
239000003193 general anesthetic agent Substances 0.000 claims description 3
229960005287 lincomycin Drugs 0.000 claims description 3
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 claims description 3
229960000485 methotrexate Drugs 0.000 claims description 3
229960002351 oleandomycin Drugs 0.000 claims description 3
235000019367 oleandomycin Nutrition 0.000 claims description 3
229960002508 pindolol Drugs 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
229960000268 spectinomycin Drugs 0.000 claims description 3
229960001294 spiramycin Drugs 0.000 claims description 3
235000019372 spiramycin Nutrition 0.000 claims description 3
229960000654 sulfafurazole Drugs 0.000 claims description 3
229960004605 timolol Drugs 0.000 claims description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 claims description 2
229940023040 Acyclovir Drugs 0.000 claims description 2
229940021383 Antiinfective irrigating solutions Drugs 0.000 claims description 2
229960005475 Antiinfectives Drugs 0.000 claims description 2
SGUAFYQXFOLMHL-UHFFFAOYSA-N Labetalol Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 2
229960005192 Methoxamine Drugs 0.000 claims description 2
WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine hydrochloride Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims description 2
229960002237 Metoprolol Drugs 0.000 claims description 2
229960002362 Neostigmine Drugs 0.000 claims description 2
ALWKGYPQUAPLQC-UHFFFAOYSA-N Neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 claims description 2
229960002748 Norepinephrine Drugs 0.000 claims description 2
229950004257 Ristocetin Drugs 0.000 claims description 2
108010081391 Ristocetin Proteins 0.000 claims description 2
229960003165 Vancomycin Drugs 0.000 claims description 2
108010059993 Vancomycin Proteins 0.000 claims description 2
229960004150 aciclovir Drugs 0.000 claims description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 2
239000000674 adrenergic antagonist Substances 0.000 claims description 2
230000002924 anti-infective Effects 0.000 claims description 2
229940121357 antivirals Drugs 0.000 claims description 2
230000001085 cytostatic Effects 0.000 claims description 2
239000000824 cytostatic agent Substances 0.000 claims description 2
229960001632 labetalol Drugs 0.000 claims description 2
210000004877 mucosa Anatomy 0.000 claims description 2
229940005943 ophthalmologic Antivirals Drugs 0.000 claims description 2
VUOPFFVAZTUEGW-FBMDODLCSA-N ristocetin Chemical compound C=1C([C@@H]2C(=O)N[C@@H]([C@@H](C3=CC=C(C=C3)OC=3C=C4C=C(C=3O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](COC5[C@@H]([C@H](O)[C@@H](O)[C@H](C)O5)O)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O[C@H]3[C@H]([C@H](O)[C@H](O)CO3)O)OC3=CC=C(C=C3)[C@@H](O)[C@@H]3C(=O)N[C@@H](C=5C=C(C(=C(O)C=5)C)OC=5C(O)=CC=C(C=5)[C@@H](N)C(=O)N3)C(=O)N[C@H]4C(=O)N2)O[C@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)C(=O)N[C@@H](C2=CC(O)=C3)C(=O)OC)=CC=C(O)C=1C2=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O VUOPFFVAZTUEGW-FBMDODLCSA-N 0.000 claims description 2
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 2
229960004306 sulfadiazine Drugs 0.000 claims description 2
229940026754 topical Antivirals Drugs 0.000 claims description 2
239000003357 wound healing promoting agent Substances 0.000 claims description 2
WRJPSSPFHGNBMG-UHFFFAOYSA-N Aceclidine Chemical compound C1CC2C(OC(=O)C)CN1CC2 WRJPSSPFHGNBMG-UHFFFAOYSA-N 0.000 claims 2
229950005779 CARBOMYCIN Drugs 0.000 claims 2
RCKMWOKWVGPNJF-UHFFFAOYSA-N Carbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 claims 2
CYDMQBQPVICBEU-XRNKAMNCSA-N Chlortetracycline Chemical group C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims 2
FQVHOULQCKDUCY-OGHXVOSASA-N [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(1S,3R,7R,8S,9S,10R,12R,14E,16S)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 claims 2
229960003216 aceclidine Drugs 0.000 claims 2
229960003974 diethylcarbamazine Drugs 0.000 claims 2
CEMAWMOMDPGJMB-CYBMUJFWSA-N (2R)-1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-CYBMUJFWSA-N 0.000 claims 1
VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 claims 1
229940088710 Antibiotic Drugs 0.000 claims 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 1
CEMAWMOMDPGJMB-UHFFFAOYSA-N Laracor Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims 1
229960001697 Physostigmine Drugs 0.000 claims 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N Physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 1
230000001800 adrenalinergic Effects 0.000 claims 1
230000000259 anti-tumor Effects 0.000 claims 1
230000001713 cholinergic Effects 0.000 claims 1
239000000812 cholinergic antagonist Substances 0.000 claims 1
229960002227 clindamycin Drugs 0.000 claims 1
230000000926 neurological Effects 0.000 claims 1
229960004570 oxprenolol Drugs 0.000 claims 1
241000894007 species Species 0.000 claims 1
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
239000000243 solution Substances 0.000 description 149
239000000727 fraction Substances 0.000 description 63
239000012153 distilled water Substances 0.000 description 56
239000002585 base Substances 0.000 description 55
230000000875 corresponding Effects 0.000 description 41
210000001508 Eye Anatomy 0.000 description 38
238000009472 formulation Methods 0.000 description 37
239000011734 sodium Substances 0.000 description 34
238000003756 stirring Methods 0.000 description 33
LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
239000002244 precipitate Substances 0.000 description 32
239000011347 resin Substances 0.000 description 31
229920005989 resin Polymers 0.000 description 31
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
238000002360 preparation method Methods 0.000 description 28
DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 27
229940083542 Sodium Drugs 0.000 description 25
229940091252 Sodium supplements Drugs 0.000 description 25
230000000694 effects Effects 0.000 description 25
229960005016 naphazoline Drugs 0.000 description 25
229920001467 poly(styrenesulfonates) Polymers 0.000 description 25
KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 25
229910052708 sodium Inorganic materials 0.000 description 25
SONNWYBIRXJNDC-VIFPVBQESA-N Phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
229960001802 Phenylephrine Drugs 0.000 description 22
150000004676 glycans Polymers 0.000 description 22
229920001282 polysaccharide Polymers 0.000 description 22
239000005017 polysaccharide Substances 0.000 description 22
150000004804 polysaccharides Polymers 0.000 description 22
239000000047 product Substances 0.000 description 22
229940097043 Glucuronic Acid Drugs 0.000 description 21
239000000178 monomer Substances 0.000 description 21
AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
239000012528 membrane Substances 0.000 description 20
230000003547 miosis Effects 0.000 description 19
210000004379 Membranes Anatomy 0.000 description 18
239000007788 liquid Substances 0.000 description 18
241000283973 Oryctolagus cuniculus Species 0.000 description 17
LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 17
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
238000000108 ultra-filtration Methods 0.000 description 14
230000004054 inflammatory process Effects 0.000 description 13
230000002906 microbiologic Effects 0.000 description 13
PRZXEPJJHQYOGF-GNAZCLTHSA-N (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one;nitric acid Chemical compound O[N+]([O-])=O.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C PRZXEPJJHQYOGF-GNAZCLTHSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 12
229960001963 Pilocarpine Nitrate Drugs 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
238000004166 bioassay Methods 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
206010061218 Inflammation Diseases 0.000 description 11
238000005259 measurement Methods 0.000 description 11
210000001519 tissues Anatomy 0.000 description 11
WDIHJSXYQDMJHN-UHFFFAOYSA-L Barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 10
229910001626 barium chloride Inorganic materials 0.000 description 10
229910052751 metal Inorganic materials 0.000 description 10
239000002184 metal Substances 0.000 description 10
239000000843 powder Substances 0.000 description 10
238000001556 precipitation Methods 0.000 description 10
229940012356 Eye Drops Drugs 0.000 description 9
GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 9
238000007792 addition Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 9
239000003889 eye drop Substances 0.000 description 9
159000000000 sodium salts Chemical class 0.000 description 9
229960005294 triamcinolone Drugs 0.000 description 9
229960001927 Cetylpyridinium Chloride Drugs 0.000 description 8
YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 8
210000004087 Cornea Anatomy 0.000 description 8
210000001747 Pupil Anatomy 0.000 description 8
239000000969 carrier Substances 0.000 description 8
238000005119 centrifugation Methods 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
239000000463 material Substances 0.000 description 8
230000002829 reduced Effects 0.000 description 8
210000002159 Anterior Chamber Anatomy 0.000 description 7
241000287828 Gallus gallus Species 0.000 description 7
239000004372 Polyvinyl alcohol Substances 0.000 description 7
238000001914 filtration Methods 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 6
210000003560 Epithelium, Corneal Anatomy 0.000 description 6
206010027646 Miosis Diseases 0.000 description 6
229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 6
239000002260 anti-inflammatory agent Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000006196 drop Substances 0.000 description 6
230000035876 healing Effects 0.000 description 6
235000021317 phosphate Nutrition 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000000725 suspension Substances 0.000 description 6
KWBUARAINLGYMG-JGMIRXPNSA-N (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO KWBUARAINLGYMG-JGMIRXPNSA-N 0.000 description 5
235000014469 Bacillus subtilis Nutrition 0.000 description 5
229950009774 Gramicidin S Drugs 0.000 description 5
229940053050 Neomycin Sulfate Drugs 0.000 description 5
229940076185 Staphylococcus aureus Drugs 0.000 description 5
241000191967 Staphylococcus aureus Species 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
150000003863 ammonium salts Chemical class 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000010452 phosphate Substances 0.000 description 5
229920002451 polyvinyl alcohol Polymers 0.000 description 5
235000019422 polyvinyl alcohol Nutrition 0.000 description 5
239000012266 salt solution Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
210000000795 Conjunctiva Anatomy 0.000 description 4
210000000554 Iris Anatomy 0.000 description 4
229960002139 Pilocarpine Hydrochloride Drugs 0.000 description 4
239000004599 antimicrobial Substances 0.000 description 4
230000001580 bacterial Effects 0.000 description 4
239000002537 cosmetic Substances 0.000 description 4
150000007529 inorganic bases Chemical class 0.000 description 4
WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
229910052744 lithium Inorganic materials 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
238000000926 separation method Methods 0.000 description 4
230000001225 therapeutic Effects 0.000 description 4
239000005526 vasoconstrictor agent Substances 0.000 description 4
229940075615 Bacillus subtilis Drugs 0.000 description 3
240000008371 Bacillus subtilis Species 0.000 description 3
JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
229960003957 Dexamethasone Drugs 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
KIUKXJAPPMFGSW-MNSSHETKSA-N Hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 3
229940099552 Hyaluronan Drugs 0.000 description 3
210000004400 Mucous Membrane Anatomy 0.000 description 3
IAIWVQXQOWNYOU-FPYGCLRLSA-N Nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 3
229960001907 Nitrofurazone Drugs 0.000 description 3
241000283977 Oryctolagus Species 0.000 description 3
108010040201 Polymyxins Proteins 0.000 description 3
241000191940 Staphylococcus Species 0.000 description 3
229960002385 Streptomycin Sulfate Drugs 0.000 description 3
NVBFHJWHLNUMCV-UHFFFAOYSA-N Sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
239000012154 double-distilled water Substances 0.000 description 3
230000002255 enzymatic Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
229960000890 hydrocortisone Drugs 0.000 description 3
230000002757 inflammatory Effects 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
210000000056 organs Anatomy 0.000 description 3
230000002688 persistence Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000011574 phosphorus Substances 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
238000000746 purification Methods 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007787 solid Substances 0.000 description 3
200000000019 wound Diseases 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
HBZVNWNSRNTWPS-UHFFFAOYSA-N 6-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(O)C2=CC(N)=CC=C21 HBZVNWNSRNTWPS-UHFFFAOYSA-N 0.000 description 2
230000035533 AUC Effects 0.000 description 2
241000194103 Bacillus pumilus Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 2
229960001334 Corticosteroids Drugs 0.000 description 2
229960001305 Cysteine Hydrochloride Drugs 0.000 description 2
229960004833 Dexamethasone phosphate Drugs 0.000 description 2
210000000883 Ear, External Anatomy 0.000 description 2
210000000981 Epithelium Anatomy 0.000 description 2
241000283086 Equidae Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
208000009883 Joint Disease Diseases 0.000 description 2
206010023332 Keratitis Diseases 0.000 description 2
241000283898 Ovis Species 0.000 description 2
229940055729 Papain Drugs 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
241000606701 Rickettsia Species 0.000 description 2
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
206010039509 Scab Diseases 0.000 description 2
229940010747 Sodium Hyaluronate Drugs 0.000 description 2
229920002385 Sodium hyaluronate Polymers 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
QIJRTFXNRTXDIP-JIZZDEOASA-N [(1R)-1-carboxy-2-sulfanylethyl]azanium;chloride;hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 2
238000003811 acetone extraction Methods 0.000 description 2
239000000061 acid fraction Substances 0.000 description 2
229920001284 acidic polysaccharide Polymers 0.000 description 2
150000004805 acidic polysaccharides Chemical class 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical group [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000004432 carbon atoms Chemical group C* 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
229960002842 clobetasol Drugs 0.000 description 2
FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
238000010908 decantation Methods 0.000 description 2
230000003247 decreasing Effects 0.000 description 2
VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 2
230000029087 digestion Effects 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000002458 infectious Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000004301 light adaptation Effects 0.000 description 2
229910003002 lithium salt Inorganic materials 0.000 description 2
159000000002 lithium salts Chemical class 0.000 description 2
238000002690 local anesthesia Methods 0.000 description 2
235000013372 meat Nutrition 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000011368 organic material Substances 0.000 description 2
PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
229960005205 prednisolone Drugs 0.000 description 2
239000002510 pyrogen Substances 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
230000001235 sensitizing Effects 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
229910052712 strontium Inorganic materials 0.000 description 2
150000003457 sulfones Chemical class 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
150000003512 tertiary amines Chemical group 0.000 description 2
239000012085 test solution Substances 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
229910052718 tin Inorganic materials 0.000 description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
PRPINYUDVPFIRX-UHFFFAOYSA-N 1-Naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 1
FEJKHHYOIOYSGL-VAOFZXAKSA-N 1-[(2R,4S,5R)-2-ethyl-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@@]1(CC)C[C@H](O)[C@@H](CO)O1 FEJKHHYOIOYSGL-VAOFZXAKSA-N 0.000 description 1
UNJJHOQIVSZFDN-RRKCRQDMSA-N 1-[(2R,4S,5R)-5-(aminomethyl)-4-hydroxyoxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CN)O[C@H]1N1C(=O)NC(=O)C(I)=C1 UNJJHOQIVSZFDN-RRKCRQDMSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
150000004325 8-hydroxyquinolines Chemical class 0.000 description 1
229940035676 ANALGESICS Drugs 0.000 description 1
210000001742 Aqueous Humor Anatomy 0.000 description 1
206010003246 Arthritis Diseases 0.000 description 1
206010003284 Arthropathy Diseases 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010060945 Bacterial infection Diseases 0.000 description 1
229940024376 Benoxinate Drugs 0.000 description 1
229960005274 Benzocaine Drugs 0.000 description 1
BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
206010005159 Blepharospasm Diseases 0.000 description 1
241000588779 Bordetella bronchiseptica Species 0.000 description 1
SPNQRCTZKIBOAX-UHFFFAOYSA-N Butralin Chemical compound CCC(C)NC1=C([N+]([O-])=O)C=C(C(C)(C)C)C=C1[N+]([O-])=O SPNQRCTZKIBOAX-UHFFFAOYSA-N 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
229960003260 Chlorhexidine Drugs 0.000 description 1
229940097572 Chloromycetin Drugs 0.000 description 1
IRPFTFQLFQCAAY-UHFFFAOYSA-N Cl.[P] Chemical compound Cl.[P] IRPFTFQLFQCAAY-UHFFFAOYSA-N 0.000 description 1
LQOLIRLGBULYKD-JKIFEVAISA-N Cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
241001478240 Coccus Species 0.000 description 1
210000001520 Comb Anatomy 0.000 description 1
210000002808 Connective Tissue Anatomy 0.000 description 1
206010011026 Corneal lesion Diseases 0.000 description 1
206010061428 Decreased appetite Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
210000002744 Extracellular Matrix Anatomy 0.000 description 1
210000000416 Exudates and Transudates Anatomy 0.000 description 1
229940013399 Flumethasone Drugs 0.000 description 1
FAOZLTXFLGPHNG-KNAQIMQKSA-N Fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
229960002949 Fluorouracil Drugs 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
DDUHZTYCFQRHIY-RBHXEPJQSA-N Griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
210000003128 Head Anatomy 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
229960004716 Idoxuridine Drugs 0.000 description 1
229960000905 Indomethacin Drugs 0.000 description 1
208000002864 Infectious Keratoconjunctivitis Diseases 0.000 description 1
206010022114 Injury Diseases 0.000 description 1
210000001503 Joints Anatomy 0.000 description 1
229960002064 Kanamycin Sulfate Drugs 0.000 description 1
206010023644 Lacrimation increased Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229940041033 Macrolides Drugs 0.000 description 1
TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
210000004080 Milk Anatomy 0.000 description 1
241000588622 Moraxella bovis Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
229950006780 N-Acetylglucosamine Drugs 0.000 description 1
229960004760 Naphazoline Hydrochloride Drugs 0.000 description 1
210000003928 Nasal Cavity Anatomy 0.000 description 1
229940097496 Nasal Spray Drugs 0.000 description 1
210000001331 Nose Anatomy 0.000 description 1
229960002950 Novobiocin Drugs 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
229940006000 Other antiinfectives in ATC Drugs 0.000 description 1
CMHHMUWAYWTMGS-UHFFFAOYSA-N Oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
IJHNSHDBIRRJRN-UHFFFAOYSA-N Pheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
231100000614 Poison Toxicity 0.000 description 1
KCLANYCVBBTKTO-UHFFFAOYSA-N Proxymetacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
210000001179 Synovial Fluid Anatomy 0.000 description 1
229960002180 Tetracycline Drugs 0.000 description 1
OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
229940040944 Tetracyclines Drugs 0.000 description 1
229940098956 Topical Powder Drugs 0.000 description 1
229960002117 Triamcinolone Acetonide Drugs 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
VSQQQLOSPVPRAZ-RRKCRQDMSA-N Trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
229960003962 Trifluridine Drugs 0.000 description 1
229960004059 Tylosin Drugs 0.000 description 1
WBPYTXDJUQJLPQ-VMXQISHHSA-N Tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
239000004182 Tylosin Substances 0.000 description 1
210000003954 Umbilical Cord Anatomy 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
229940029983 VITAMINS Drugs 0.000 description 1
241000700605 Viruses Species 0.000 description 1
229940021016 Vitamin IV solution additives Drugs 0.000 description 1
210000004127 Vitreous Body Anatomy 0.000 description 1
229920004482 WACKER® Polymers 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960000276 acetophenazine Drugs 0.000 description 1
NUKVZKPNSKJGBK-SPIKMXEPSA-N acetophenazine dimaleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 NUKVZKPNSKJGBK-SPIKMXEPSA-N 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
230000001154 acute Effects 0.000 description 1
230000001464 adherent Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000000240 adjuvant Effects 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003942 amphotericin B Drugs 0.000 description 1
230000000202 analgesic Effects 0.000 description 1
230000003042 antagnostic Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
201000008804 arthropathy Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
150000001555 benzenes Chemical group 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
VQODGRNSFPNSQE-DVTGEIKXSA-N betamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-DVTGEIKXSA-N 0.000 description 1
229950006991 betamethasone phosphate Drugs 0.000 description 1
230000000744 blepharospasm Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
201000009030 carcinoma Diseases 0.000 description 1
NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical class CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
229960003326 cloxacillin Drugs 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
231100000478 corneal permeability Toxicity 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
230000001472 cytotoxic Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000002354 daily Effects 0.000 description 1
239000002781 deodorant agent Substances 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
230000000249 desinfective Effects 0.000 description 1
PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical class [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
125000005131 dialkylammonium group Chemical group 0.000 description 1
201000009910 diseases by infectious agent Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000534 elicitor Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical group CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960003469 flumetasone Drugs 0.000 description 1
WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
229960001048 fluorometholone Drugs 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
229960002867 griseofulvin Drugs 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000003054 hormonal Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
OCYSGIYOVXAGKQ-UHFFFAOYSA-N hydron;3-[1-hydroxy-2-(methylamino)ethyl]phenol;chloride Chemical compound Cl.CNCC(O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000640 hydroxylating Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
230000004317 lacrimation Effects 0.000 description 1
230000002045 lasting Effects 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
230000000670 limiting Effects 0.000 description 1
238000011068 load Methods 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229960003640 mafenide Drugs 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000006011 modification reaction Methods 0.000 description 1
230000002911 mydriatic Effects 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
230000003287 optical Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960003502 oxybuprocaine Drugs 0.000 description 1
230000003071 parasitic Effects 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
239000000546 pharmaceutic aid Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
239000002574 poison Substances 0.000 description 1
230000001376 precipitating Effects 0.000 description 1
230000002335 preservative Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
229960003981 proparacaine Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000979 retarding Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001568 sexual Effects 0.000 description 1
231100000486 side effect Toxicity 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000000475 sunscreen Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival Effects 0.000 description 1
230000002459 sustained Effects 0.000 description 1
125000005207 tetraalkylammonium group Chemical group 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000005208 trialkylammonium group Chemical group 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229960005041 troleandomycin Drugs 0.000 description 1
LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
235000019375 tylosin Nutrition 0.000 description 1
JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
230000000033 vasopressor Effects 0.000 description 1
244000052613 viral pathogens Species 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamins Natural products 0.000 description 1